lestaurtinib

lestaurtinib information and resources from the National Cancer Institute

NCI Thesaurus | lestaurtinib

An orally bioavailable indolocarbazole derivative with antineoplastic properties. Lestaurtinib inhibits autophosphorylation of FMS-like tyrosine kinase 3 (FLT3), resulting in inhibition of FLT3 activity and induction of apoptosis in tumor cells that overexpress FLT3. NCI Thesaurus | lestaurtinib

An orally bioavailable indolocarbazole derivative with antineoplastic properties. Lestaurtinib inhibits autophosphorylation of FMS-like tyrosine kinase 3 (FLT3), resulting in inhibition of FLT3 activity and induction of apoptosis in tumor cells that overexpress FLT3.

ASH: Oral Targeted Agent Boosts Remissions in Poor-Prognosis AML Dec 14, 2005
MedPage Today, ...from an ongoing study. The drug, labeled CEP-701, or lestaurtinib, inhibits the receptor tyrosine kinase FLT3. Nearly a third of ...

Scientific Advances on Three Lead Cephalon Oncology Compounds to ... Dec 8, 2005
PR Newswire (press release), ...sponsored Phase 2 multi-center registration studies on two Cephalon Oncology investigational compounds, TREANDA(R) (bendamustine HCL) and CEP-701 (lestaurtinib ...

Scientific Advances on Three Lead Cephalon Oncology Compounds to ... Dec 8, 2005
Yahoo! News (press release) ...sponsored Phase 2 multi-center registration studies on two Cephalon Oncology investigational compounds, TREANDA® (bendamustine HCL) and CEP-701 (lestaurtinib ...

Cephalon Oncology Reports Clinical Response to CEP-701 Correlates ... Dec 12, 2005
PR Newswire (press release), 12 /PRNewswire-FirstCall/ -- Laboratory findings demonstrate that the anti-cancer compound CEP-701 (lestaurtinib) inhibits a specific genetic mutation targeted ...

Cephalon Oncology Reports High Response Rates to Single Agent ... Dec 12, 2005
PR Newswire (press release), ...arsenic trioxide) injection, an intravenous arsenic-based targeted therapy; TREANDA, a multi- functional hybrid cytotoxic; and CEP-701 (lestaurtinib), an oral ...

lestaurtinib -->